Sign in

Biologics Is Fastest Growing Segment Fueling The Growth Of Eosinophilic Esophagitis Market

Sushil Mahalle's Articles
Biologics Is Fastest Growing Segment Fueling The Growth Of Eosinophilic Esophagitis Market

Market Overview:

Eosinophilic esophagitis is a chronic immune/antigen-mediated esophageal disease characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation. Biologic therapy like monoclonal antibodies is an emerging and promising segment for treatment with minimal side effects.

Market key trends:

One of the key trends driving the market growth is increasing approval and availability of biologic therapy as a targeted treatment approach. Biologics are complex protein based recombinant therapeutic agents that can be used to selectively target inflammatory cascades leading to esophageal eosinophilia. Recently, dupilumab, an IL-4R alpha inhibitor, has received FDA approval for treatment of eosinophilic esophagitis based on positive clinical trial results demonstrating its efficacy and favorable safety profile.

The global Eosinophilic Esophagitis Market Growth is estimated to be valued at US$ 245.92 Mn in 2023 and is expected to exhibit a CAGR of 33.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Segment Analysis

The global Eosinophilic Esophagitis market is dominated by the drug therapy segment. This is because drug therapy is currently the first line treatment option prescribed for eosinophilic esophagitis. Within drug therapy, topical corticosteroids form the largest sub-segment as they are effective in mitigating inflammation and symptoms. However, biologics which target specific cytokines and immune cells involved in the disease pathogenesis are expected to witness higher growth during the forecast period.

Key Takeaways

The global Eosinophilic Esophagitis market is expected to witness high growth, exhibiting 33.% CAGR over the forecast period, due to increasing prevalence of food allergies and gastrointestinal disorders.

Regional analysis

North America currently dominates the global market and is expected to remain the highest revenue generating region during the forecast period. This is attributed to increasing diagnosis rates, rising awareness about the disease, and strong presence of key players in the region. Asia Pacific is anticipated to witness fastest growth rate during the forecast period owing to growing health expenditures, rise in patient population, and increasing initiatives to spread awareness regarding eosinophilic esophagitis in the region.

Key players

Key players operating in the Eosinophilic Esophagitis market are Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH.

Read More: https://www.ukwebwire.com/growth-in-the-global-eosinophilic-esophagitis-market-trend-and-share-analysis/


Sushil Mahalle's Articles
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more